Seminars in arthritis and rheumatism最新文献

{"title":"Tuft resorption in patients with psoriatic arthritis","authors":"Fadi Kharouf ,&nbsp;Shangyi Gao ,&nbsp;Daniel Pereira ,&nbsp;Cheryl F Rosen ,&nbsp;Richard J Cook ,&nbsp;Vinod Chandran ,&nbsp;Dafna D Gladman","doi":"10.1016/j.semarthrit.2025.152701","DOIUrl":"10.1016/j.semarthrit.2025.152701","url":null,"abstract":"<div><h3>Objectives</h3><div>Tuft resorption (TR) is an important radiographic feature of psoriatic arthritis (PsA). We aimed to define the prevalence of TR in patients with PsA, the clinical and radiographic features associated with it, and the risk factors for its occurrence.</div></div><div><h3>Methods</h3><div>We included patients with PsA followed at our prospective observational cohort. We defined TR as resorptive changes in the terminal tufts of the fingers or toes. We used generalized estimating equations to characterize clinical and radiographic features cross-sectionally associated with TR. We used multivariate Cox regression analysis to identify factors associated with the development of TR.</div></div><div><h3>Results</h3><div>Of the 1303 patients included in the study, 526 (40.4 %) were observed to have TR, of whom 181 (34.4 %) developed it during follow-up. TR was associated with older age (OR 1.49, <em>p</em> &lt; 0.01), longer duration of PsA (OR 1.03, <em>p</em> &lt; 0.01), higher radiographic damaged joint count (OR 1.02, <em>p</em> = 0.04), axial disease (OR 1.73, <em>p</em> &lt; 0.01), and the number of systemic disease-modifying anti-rheumatic drugs (DMARDs) used (OR 1.27, <em>p</em> &lt; 0.01). Male sex (HR 1.54, <em>p</em> = 0.01), vertebral osteopenia (HR 1.39, <em>p</em> = 0.02), and use of non-steroidal anti-inflammatory drugs (HR 1.43, <em>p</em> = 0.03) were associated with the development of TR. Use of biologic and targeted synthetic DMARDs was protective (HR 0.70, <em>p</em> = 0.05), although not significant at the 5 % level.</div></div><div><h3>Conclusion</h3><div>TR is a common radiographic feature of PsA. It is associated with more severe disease, including peripheral and axial radiographic damage.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152701"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mechanisms underlying thrombosis in systemic lupus erythematosus – A Systematic review","authors":"Mads L Larsen ,&nbsp;Laura Nørgaard ,&nbsp;Petrus Linge ,&nbsp;Julie B Larsen ,&nbsp;Henrik Z Langkilde ,&nbsp;Ellen M Hauge ,&nbsp;Steffen Thiel ,&nbsp;Anne Voss ,&nbsp;Anders Bengtsson ,&nbsp;Anne Troldborg","doi":"10.1016/j.semarthrit.2025.152707","DOIUrl":"10.1016/j.semarthrit.2025.152707","url":null,"abstract":"<div><div>Patients with systemic lupus erythematosus (SLE) face an approximately 30 % risk of thrombosis post-diagnosis. However, there remains significant knowledge gaps regarding causative mechanisms, and there is a lack of specific antithrombotic guidelines.</div><div>This systematic review aims to examine the existing literature regarding the mechanisms contributing to thrombosis risk in SLE, focusing on five predefined procoagulant domains: autoantibodies (including antiphospholipid antibodies (aPL)), the complement system, platelets, the endothelium, and the coagulation system. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) statements and searched in PubMed and Embase without time restrictions. Risk of bias assessment was performed using a pre-specified evaluation tool.</div><div>Out of 3,747 initially identified publications, 30 studies were included, with 28 demonstrating robust methodological quality in the risk of bias assessment. The studies were experimental, involving blood samples from cross-sectional SLE cohorts, except one animal -and one case-control study. We identified six different thrombosis mechanisms of action. Most studies concentrated on autoantibodies, predominantly aPL. Shared mechanisms between aPL and other autoantibodies may account for the increased thrombosis risk in aPL-negative SLE patients. Significant knowledge gaps remain, particularly regarding the role of the complement system in SLE-related thrombosis. Also, most research relies on cross-sectional designs, emphasizing the need for prospective cohort studies to better assess clinical factors. Finally, comprehensive studies examining the interactions between multiple procoagulant factors and their link to thrombosis are lacking. Closing these gaps in future research could improve both preventive and personalized treatment strategies for thrombosis in SLE.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152707"},"PeriodicalIF":4.6,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143620111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of frailty and prefrailty in systemic lupus erythematosus: A systematic review and meta-analysis","authors":"Ni Sang ,&nbsp;Hong-hui Zhang ,&nbsp;Meng-yao Zhang ,&nbsp;Ming-hui Zhang ,&nbsp;Yan-qin Zhu ,&nbsp;Hui Chen ,&nbsp;You Sun ,&nbsp;Meng-cheng Cheng ,&nbsp;Guo-cui Wu","doi":"10.1016/j.semarthrit.2025.152709","DOIUrl":"10.1016/j.semarthrit.2025.152709","url":null,"abstract":"<div><h3>Objective</h3><div>Frailty is associated with mortality in systemic lupus erythematosus (SLE), but the prevalence is unclear. The aim of this systematic review and meta-analysis was to investigate the prevalence of frailty and prefrailty in SLE patients.</div></div><div><h3>Methods</h3><div>Four databases, namely PubMed, Cochrane, EMBASE, and Web of Science, were systematically searched from their inception to November 2024 to identify studies that fulfilled the predefined a priori inclusion criteria for systematic review and meta-analysis, and that specifically investigated frailty and prefrailty in patients with SLE. The quality assessment of the included studies was conducted according to the Newcastle-Ottawa scale (NOS).</div></div><div><h3>Results</h3><div>Fifteen studies were retrieved according to the inclusion criteria, and their data were combined in the eventual review. Data from studies including 46,060 patients with SLE were included. The analysis showed that the pooled prevalence of frailty in patients with SLE was 27 % (95 % CI: 19 % - 36 %), the pooled prevalence of prefrailty was 65 % (95 % CI: 54 % - 76 %). Analysis of subgroups revealed that the prevalence of frailty was 26 % (95 % CI: 14 % to 41 %) when measured by Systemic Lupus International Collaborating Clinics-Frailty Index (SLICC-FI) and 22 % (95 % CI: 18 % to 26 %) when assessed using Fried phenotype (FP).</div></div><div><h3>Conclusion</h3><div>Both frailty and prefrailty are highly prevalent conditions among patients with SLE. There is an urgent need to better understand and address frailty in this population to enhance patient outcomes and quality of life.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152709"},"PeriodicalIF":4.6,"publicationDate":"2025-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143611111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association of cervical and lumbar mobility with functional ability in axial spondyloarthritis: Insights from the CASTRO registry using Inertial Measurement Unit system","authors":"Diana Maria Margareta Moldovan ,&nbsp;I. Concepción Aranda-Valera ,&nbsp;Lourdes Ladehesa-Pineda ,&nbsp;María Carmen Ábalos-Aguilera ,&nbsp;María Ángeles Puche-Larrubia ,&nbsp;Alejandro Escudero-Contreras ,&nbsp;Cristina González-Navas ,&nbsp;Juan Luis Garrido-Castro ,&nbsp;Daniela Fodor ,&nbsp;Eduardo Collantes-Estévez ,&nbsp;Clementina López-Medina","doi":"10.1016/j.semarthrit.2025.152703","DOIUrl":"10.1016/j.semarthrit.2025.152703","url":null,"abstract":"<div><h3>Objective</h3><div>This study aimed to evaluate the association of cervical and lumbar mobility with functional ability in patients with axial spondyloarthritis (axSpA) using an inertial measurement unit (IMU) sensor system, as well as the influence of disease duration on this association.</div></div><div><h3>Methods</h3><div>This cross-sectional study included 156 patients with axSpA from the Córdoba axSpA Task Force Registry and Outcomes (CASTRO) registry. Spinal mobility was assessed with the IMU system and functional ability was measured using the Bath Ankylosing Spondylitis Functional Index (BASFI). Patients were categorized into non-longstanding (≤23 years) and longstanding (&gt;23 years) groups based on the median disease duration. Univariable and multivariable linear regressions were conducted to evaluate the variability of BASFI explained by each spinal movement (coefficient of determination [R²]).</div></div><div><h3>Results</h3><div>Multivariable linear regression analysis showed that cervical movements collectively explained 19.9 % (R² = 0.199) of BASFI variability, while lumbar mobility accounted for 11.3 %. Among longstanding axSpA patients, cervical rotation (unstandardized regression coefficient [<em>B</em>] = -0.68, 95 % CI1.13 to -0.24) and lumbar flexion (<em>B</em> = 0.65, 95 % CI 0.05 to 1.24), were independently associated with the BASFI scores. In non-longstanding patients, lumbar mobility, particularly lumbar rotation (<em>B</em> = -0.51, 95 % CI0.97 to -0.05), showed a stronger association with functional ability.</div></div><div><h3>Conclusions</h3><div>This study suggests that cervical mobility is more strongly associated with functional ability than lumbar mobility in axSpA patients. However, the impact of cervical and lumbar mobility on functional ability varies with disease duration.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152703"},"PeriodicalIF":4.6,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143593125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pathogenesis and targets in uveitis","authors":"Professor Athimalaipet V Ramanan","doi":"10.1016/j.semarthrit.2025.152692","DOIUrl":"10.1016/j.semarthrit.2025.152692","url":null,"abstract":"<div><div>Uveitis is the most common ocular finding in systemic rheumatic diseases. It is a potentially sight threatening disease seen on its own or in association with systemic rheumatic diseases. Whilst significant advances have been made with biological and small molecular therapies for conditions such as rheumatoid arthritis (RA), ankylosing spondylisitis (AS), juvenile idiopathic arthritis (JIA) and psoriatic arthritis (PsA), the evidence base for managing the ocular complications from these diseases, particularly uveitis, is still limited.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152692"},"PeriodicalIF":4.6,"publicationDate":"2025-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is mixed connective tissue disease (MCTD) a subtype of systemic sclerosis?","authors":"Yoshiya Tanaka","doi":"10.1016/j.semarthrit.2025.152678","DOIUrl":"10.1016/j.semarthrit.2025.152678","url":null,"abstract":"<div><div>In 1972, mixed connective tissue disease (MCTD) was proposed by Sharp et al. as a disease entity characterized by overlapping clinical features of systemic lupus erythematosus, systemic sclerosis (SSc), and polymyositis, as well as high titers of serum anti-U1-RNP antibody. However, the disease concept of MCTD is sometimes far from being sufficiently acknowledged. We, therefore, reported the revised diagnostic criteria for MCTD 2019 by consensus method and evaluation using clinical data of typical and borderline cases of MCTD. The disease entity of MCTD and its difference from SSc can be further emphasized by 1) microvasculopathy detected using nailfold videocapillaroscopy, 2) statistical clustering based on immunophenotypic analysis using flow cytometry, 3) immune cell-specific gene regulation, 4) clinical relevance of anti-SMN complex antibodies.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152678"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Progress in APS pregnancy: Results from the IMPACT trial","authors":"Jane E. Salmon ,&nbsp;Marta Guerra ,&nbsp;Mimi Kim ,&nbsp;D. Ware Branch","doi":"10.1016/j.semarthrit.2025.152689","DOIUrl":"10.1016/j.semarthrit.2025.152689","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152689"},"PeriodicalIF":4.6,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143586806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racial disparity of lung cancer risk in people with rheumatoid arthritis","authors":"Yi-Sheng Jhang ,&nbsp;Yu-Jung Su ,&nbsp;Hui-Chin Chang ,&nbsp;Shih-Chi Yang ,&nbsp;Shiu-Jau Chen ,&nbsp;Shuo-Yan Gau","doi":"10.1016/j.semarthrit.2025.152702","DOIUrl":"10.1016/j.semarthrit.2025.152702","url":null,"abstract":"","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152702"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementing the PEIR Framework and PEIRS-22 to facilitate improved and sustainable patient engagement in OMERACT","authors":"Caitlin Jones ,&nbsp;Clayon Hamilton ,&nbsp;Peter Tugwell ,&nbsp;Shawna Grosskleg ,&nbsp;Catherine Hofstetter ,&nbsp;Ben Horgan ,&nbsp;Alison Hoens ,&nbsp;Dorcas Beaton","doi":"10.1016/j.semarthrit.2025.152704","DOIUrl":"10.1016/j.semarthrit.2025.152704","url":null,"abstract":"<div><h3>Background</h3><div>OMERACT (Outcome Measures in Rheumatology) is an international initiative focused on improving outcome measurement in rheumatology research, fostering collaboration among PRPs, clinicians, and researchers to develop Core Outcome Sets. The 22-item Patient Engagement In Research Scale (PEIRS-22) is a tool designed to measure the level of meaningful patient engagement and guide efforts towards improvement.</div></div><div><h3>Aim</h3><div>1) To describe the current profile of patient engagement at OMERACT using the scores generated by the PEIRS-22 and 2) to assess the validity of the PEIRS-22 within the OMERACT group of PRPs.</div></div><div><h3>Methods</h3><div>We administered the PEIRS-22 to assess the level of meaningful engagement of PRPs with OMERACT. We compared the scores with self-rated participant engagement, and asked open ended questions to investigate the validity of the tool in the OMERACT PRP population.</div></div><div><h3>Results</h3><div>Overall engagement was meaningful and correlated to self-reported level of engagement. However, there were components and items that were flagged as priorities for improvement (Convenience, Benefits and Team Environment, and specifically items PR11: I participated in making decisions about the project, T2: I was an equal partner in the research project team, and SU1: I received sufficient support to contribute to the project.</div></div><div><h3>Conclusion</h3><div>This study highlights the validity of the PEIRS-22 within OMERACT and reveals satisfactory levels of meaningful PRP engagement. As OMERACT continues to learn and evolve, the PEIRS-22 will be integral in developing a structured and consistent approach to patient engagement.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152704"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143549205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Remission in gout is possible: 5-year follow-up in the NOR-Gout study","authors":"Till Uhlig ,&nbsp;Johan Stjärne ,&nbsp;Lars Fridtjof Karoliussen ,&nbsp;Joe Sexton ,&nbsp;Tron Eskild ,&nbsp;Sella Aarrestad Provan ,&nbsp;Espen André Haavardsholm ,&nbsp;Hilde Berner Hammer","doi":"10.1016/j.semarthrit.2025.152698","DOIUrl":"10.1016/j.semarthrit.2025.152698","url":null,"abstract":"<div><h3>Objective</h3><div>To compare the performance of remission definitions for gout in an observational treat-to-target patient cohort with 5 years of follow-up.</div></div><div><h3>Methods</h3><div>Inclusion criteria were crystal proven gout with increased serum urate levels and a flare. Remission was determined according to the 2016 preliminary gout remission definition, a modified preliminary definition with more lenient thresholds for the individual variables pain due to gout and patient global assessment of gout disease activity, and the simplified definition without patient reported outcomes. Linear mixed models were used to compare quality of life with SF-36 physical (PCS) and mental (MCS) components and structural damage with semiquantitative dual energy tomography (DECT) across patients fulfilling and not fulfilling each remission definition.</div></div><div><h3>Results</h3><div>Data were analysed from 211 patients (mean age 56.4 years, 95.3 % males) included in an intensive one-year treat-to-target intervention with follow-up at 1, 2, and 5 years. The frequency of remission increased for both the preliminary definition at 1, 2 and 5 years (4.6 %, 22.1 %, and 42.8 %), the modified preliminary definition (5.1 %, 28.4 %, and 44.1. %) and the simplified definition (7.7 %, 45.4 %, and 58.6 %)(<em>p</em> &lt; 0.001 for all definitions). The simplified definition identified more patients in remission than the preliminary and the modified preliminary definition at years 2 and 5. All three definitions discriminated for SF-36 MCS, PCS or DECT.</div></div><div><h3>Conclusion</h3><div>Remission in gout after urate lowering therapy was seldom after 1 but high after 5 years and was highest for the simplified definition. Remission definitions showed concurrent validity for quality of life and structural changes.</div></div>","PeriodicalId":21715,"journal":{"name":"Seminars in arthritis and rheumatism","volume":"72 ","pages":"Article 152698"},"PeriodicalIF":4.6,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143577298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}